Effect of cyclosporine, dexamethasone, and human CTLA4-ig on production of cytokines in lymphocytes of clinically normal cats and cats undergoing renal transplantation

American Journal of Veterinary Research

Volumn 72, Issue 4, 2011, Pages 541-549

  Aronson, Lillian R ^a   Stumhofer, Jason S ^b   Drobatz, Kenneth J ^a   Hunter, Christopher A ^b  

^a Clinical Studies   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; CYTOKINE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MITOGENIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CAT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RANK SUM TEST; WILCOXON SIGNED RANKS TEST; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG COMBINATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY;

ANIMALIA; FELIDAE;

ANIMALS; ANTIGENS, CD; CATS; CELL PROLIFERATION; CONCANAVALIN A; CYCLOSPORINE; CYTOKINES; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MITOGENS;

EID: 79955543003     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.4.541     Document Type: Article

References (65)

1. Katayama M, McAnulty J F. Renal transplantation in cats: techniques, complications, and immunosupression. Compend Con-tin Educ Pract Vet 2002;24:874-882.
2. Katayama M, McAnulty. Renal transplantation in cats: patient selection and preoperative management. Compend Contin Educ Pract Vet 2002;24:868-872.
3. Bernsteen L, Gregory CR, Kyles AE, et al. Renal transplantation in cats. Clin Tech Small Anim Pract 2000;15:40-45.
4. Gregory CR. Renal transplantation in cats. Compend Contin Educ Pract Vet 1993;15:1325-1338.
5. Gregory CR. Renal transplantation. In: Bojrab MJ, ed. Current techniques in small animal surgery. 4th ed. Baltimore: Williams & Wilkins, 1998;434.
6. Kadar E, Sykes JE, Kass PH, et al. Evaluation of the prevalence of infections in cats after renal transplantation: 169 cases (1987-2003). J Am Vet Med Assoc 2005;227:948-953.
7. Bernsteen L, Gregory CR, Aronson LR, et al. Acute toxoplasmo-sis following renal transplantation in three cats and a dog. J Am Vet Med Assoc 1999;215:1123-1126.
8. Nordquist BC, Aronson LR. Pyogranulomatous cystitis associated with Toxoplasma gondii infection in a cat after renal transplantation. J Am Vet Med Assoc 2008;232:1010-1012.
9. Griffn AG, Newton AL, Aronson LR, et al. Disseminated Myco-bacterium avium complex infection following renal transplantation in a cat. J Am Vet Med Assoc 2003;222:1097-1101.
10. Wooldridge J, Gregory CR, Mathews KG, et al. The prevalence of malignant neoplasia in feline renal transplant recipients. Vet Surg 2002;31:94-97.
11. Schmiedt C W, Grimes JA, Holzman G, et al. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression. Vet Comp Oncol 2009;7:45-53.
12. Mathews KG, Gregory CR. Renal transplants in cats: 66 cases (1987-1996). J Am Vet Med Assoc 1997;211:1432-1436.
13. Schmiedt C W, Holzman G, Schwarz T, et al. Survival, complications and analysis of risk factors after renal transplantation in cats. Vet Surg 2008;37:683-695.
14. Kyles AE, Gregory CR, Griffey SM, et al. Evaluation of the clinical and histological features of renal allograft rejection in cats. Vet Surg 2002;31:49-58.
15. Amirzargar A, Lessanpezeshki M, Fathi A, et al. Th1/Th2 cyto-kine analysis in Iranian renal transplant recipients. Transplant P ro c 2005;37:2985-2987.
16. Saalmuller A. New understanding of immunological mechanisms. Vet Microbiol 2006;117:32-38.
17. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by fow cytometry, according to immunosuprression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant 1999;13:400-409.
18. Mosmann TR, Fowell DJ. The Th1/Th2 paradigm in infections. In: Kaufman SHE, Sher A, Ahmed R, eds. Immunology of infectious diseases. Washington, DC: ASM Press, 2002;163-174.
19. Andre S, Tough D F, Lacroix-Desmazes S, et al. Surveillance of antigen presenting cells by CD4+CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 2009;174:1575-1587.
20. Hashimoto M, Sakaguchi S. Contribution of Th-1, Th-2, TH-17 or regulatory T cells to connective tissue diseases [in Japanese]. Nippon Rinsho 2009;67:482-486.
21. Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T cell activation and expansion. J Allergy Clin Immunol 2009;123:749-755.
22. Turka LA. Normal immune responses. In: Norman DJ, Suki WN, eds. Primer on transplantation. Thorofare, NJ: American Society of Transplant Physicians, 1998;7-20.
23. Basak U, Mitra DK, Panigrahi A, et al. Clinical relevance of monitoring cytokine production following living donor renal transplantation. Transplant Proc 2003;35:404-406.
24. Poole KL, Gibbs PJ, Evans PR, et al. Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transplant Immunol 2001;8:259-265.
25. Li L, Yuhai Z. The relationship between cytokines in MLC su-pernatants and acute rejection after renal transplantation. Transplant Proc 2000;32:2531-2534.
26. Divate SA. Acute renal allograft rejection: progress in under-standing cellular and molecular mechanisms. J Postgrad Med 2000;46:293-296.
27. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the frst 10 days of kidney transplantation. Clin Transplant 1997;63:374-380.
28. Sadeghi MI, Daniel V, Weimer R, et al. Differential early post-transplant cytokine responses in living and cadaver donor renal allografts. Transplantation 2003;75:1351-1355.
29. Gibbs PJ, Sadek SA, Cameron C, et al. Immunomonitoring of renal transplant recipients in the early posttransplant period by analysis of cytokine gene expression in peripheral blood mono-nuclear cells. Transplant Proc 2001;33:3285-3286.
30. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-1049.
31. Najafan N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Exp Opin Invest Drugs 2000;9:2147-2157.
32. Schaub M, Stadlbauer THW, Chandraker A, et al. Comparative strategies to induce long term graft acceptance in fully allergenic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol 1998;9:891-898.
33. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94:8789-8794.
34. Kurlberg G, Haglind E, Schon K, et al. Blockade of the B7-CD28 pathway by ctla4-Ig counteracts rejection and prolongs survival in small bowel transplantation. Scand J Immunol 2000;51:224-230.
35. Turka LA, Linsley PS, Lin H, et al. T cell activation by CD28 ligand B7 is required for cardiac allograft rejection in vivo. P ro c Natl Acad Sci U S A 1992;89:11102-11105.
36. Sayegh MH, Zheng XG, Magee C, et al. Donor antigen is necessary for the prevention of chronic rejection in CTLA4-Ig treated murine cardiac allograft recipients. Transplantation 1997;64:1646-1650.
37. Russell ME, Hancock W W, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4-Ig modulates T cell and macro-phage activation and attenuates arteriosclerosis. J Clin Invest 1996;97:833-838.
38. Azuman H, Chandraker A, Nadeau K, et al. Blockade of T cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996;93:12439-12444.
39. Lin H, Bollong S F, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor specific transfusions. J Exp Med 1993;175:1801-1806.
40. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998;101:2309-2318.
41. Akalin E, Chandraker A, Russell ME, et al. CD28-B7 T cell costimulatory blockade by CTLA4-Ig in the rat renal allograft model. Transplantation 1996;62:1942-1945.
42. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
43. Aronson LR, Drobatz KJ, Hunter CA, et al. Effects of CD28 blockade on subsets of naïve T cells in cats. Am J Vet Res 2005;66:483-492.
44. Boyum A. A one stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity feld. Scand J Clin Lab Invest Suppl 1968;S97:51-76.
45. Gregory CR, Taylor NJ, Willits NH, et al. Response to isoantigens and mitogens in the cat: effects of cyclosporin A. Am J Vet Res 1987;48:126-130.
46. Haczku A, Alexander A, Brown P, et al. The effect of dexamethasone, cyclosporine and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocor-ticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol 1994;93:510-519.
47. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997;100:3173-3183.
48. Walker C, Malik R, Canfeld PJ. Analysis of leucocytes and lymphocyte subsets in cats with naturally-occurring cryptococcosis but differing feline immunodefciency virus status. Aust Vet J 2006;72:93-97.
49. Saggi BH, Fisher RA, Bu RA, et al. Intragraft cytokine expression and tolerance induction in rat renal allografts. Transplantation 1999;67:206-210.
50. Jiang H, Wynn C, Pan F, et al. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002;73:1808-1817.
51. Daniel V, Naujokat C, Sadeghi M, et al. Association of circulating interleukin (IL)-12 and IL-10 producing dendritic cells with time posttransplant, dose of immunosupression, and plasma cytokines in renal-transplant recipients. Transplantation 2005;79:1498-1506.
52. Wang SC, Zeevi A, Jordan ML, et al. FK506, rapamycin and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T helper 2 cell line. Transplant Proc 1991;23:2920-2922.
53. Salicru AN, Sams C F, Marshall GD. Cooperative effects of cor-ticosteroids and catecholamines upon immune deviation of the type-1/type-2 cytokine balance in favor of type-2 expression in human peripheral blood mononuclear cells. Brain Behav Immun 2007;21:913-920.
54. Kuga K, Nishifuji K, Iwasaki T. Cyclosporine A inhibits transcription of cytokine genes and decreases the frequencies of IL-2 producing cells in feline mononuclear cells. J Vet Med Sci 2008;70:1011-1016.
55. Kim W, Cho ML, Kim SI, et al. Divergent effects of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000;27:324-331.
56. Halloran P F, Leung Lui S. Approved immunosupressants. In: Primer on transplantation. Thorofare, NJ: American Society of Transplant Physicians, 1998;93-102.
57. Kahan BD, Yoshimura N, Pellis NR, et al. Pharmacodynamics of cyclosporine. Transplant Proc 1986;18(suppl 5):238-251.
58. Bessler H, Kagazanov S, Punsky I, et al. Effect of dexamethasone on IL-10 and Il-12p40 production in newborns and adults. Biol Neonate 2001;80:262-266.
59. Torres KCL, Antonelli LRV, Souza ALS, et al. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 2005;166:144-157.
60. Visser J, van Boxel-Dezaire A, Methorst D, et al. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998;91:4255-4264.
61. Martinez OM, Villanuera JC, Lawrence-Miyasaki L, et al. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995;59:519-524.
62. Stylianou E, Aukrust P, Kvale D, et al. IL-1 in HIV infection: increasing serum IL-10 levels with disease progression-down regulatory effects of potent anti-retroviral therapy. Clin Exp Immunol 1999;116:115-120.
63. Reuter H, Burgess LJ, Carstens ME, et al. Characterization of the immunological features of tuberculosis pericardial effusions in HIV positive and HIV negative patients in contrast with non-tuburculosis effusions. Tuberculosis 2006;86:125-133.
64. Maxwell L, Singh JL. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;7:CD007277.
65. Ponder K P, Wang B, Wang P, et al. Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol Ther 2006;14:5-13.